Navigation Links
Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
Date:2/6/2012

NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at GenVec, Inc. ("GenVec" or the "Company") (Nasdaq: GNVC).   

(Logo:  http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that GenVec's much publicized product, TNFerade, designed for the treatment of certain cancers and infectious diseases (HIV, malaria, influenza, foot-and-mouth disease, respiratory syncytial virus, and HSV-2), was not effective.

On March 29, 2010, GenVec announced that it was discontinuing its Phase III clinical trial of TNFerade in patients with locally advanced pancreatic cancer. On this news, the Company's stock price declined by $20.10 per share – from $28.10 per share on March 29, 2010 to a close of $8.00 per share on March 30, 2010 – a decline of more than 71.5% on unusually high volume.

Request more information now by clicking here:  www.faruqilaw.com/GNVC

Take Action

If you purchased GenVec securities between March 12, 2009 and March 30, 2010 and would like to discuss your legal rights, visit www.faruqilaw.com/GNVC.  You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding GenVec's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential matter.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Smith & Nephew Reaches Settlement With US Government
2. In Honor of American Heart Month, Joy Behar & Daughter Eve Call on Women to Take the ProHeart Pledge on Facebook
3. Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Arias Technology
4. Tris Pharma Announces Appointment of Dr. Mahdi Fawzi as Top R&D Executive
5. Validation & Compliance Institute Provides Affordable Online FDA Training
6. Radient Pharmaceuticals Introduces its 2012 Sales, Advertising & Outreach Plan Presentation
7. Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results:
8. Niagara Thermal Products LLC Announces the Acquisition of J. Kittredge & Sons, Inc.
9. MD&M West 2012 to Feature Twenty Collocated Conferences
10. Berkery Noyes Releases 2011 Pharma & Healthcare Information and Technology Industry Mergers & Acquisitions Report
11. W. L. Gore & Associates Named a Top U.S. Workplace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):